TransCode Therapeutics (RNAZ) vs TherapeuticsMD (TXMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TherapeuticsMD (TXMD) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 3.9% versus a loss of 86.6%. Over five years, TXMD leads with a -94.1% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $19.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNAZ | TXMD |
|---|---|---|
| Share price | $1.16 | $1.71 |
| Market cap | $20.07M | $19.79M |
| 1-day change | -10.77% | -5.52% |
| YTD return | -83.02% | +4.91% |
| 1-year return | -86.57% | -3.93% |
| 5-year return | -100.00% | -94.10% |
| P/E ratio (TTM) | — | 171.00 |
| Forward P/E | — | 4.89 |
| EPS (TTM) | $-47.95 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.02M |
| Revenue growth (YoY) | — | +71.61% |
| Net income (latest FY) | $-34.66M | $-569.00K |
| Operating margin | — | -145.27% |
| Net margin | — | -18.83% |
| 52-week high | $12.60 | $2.95 |
| 52-week low | $1.01 | $1.43 |
| Distance from 52-week high | -90.79% | -42.03% |
| Average volume | 52.03K | 24.50K |
| Shares outstanding | 17.30M | 11.57M |
| Employees | 12 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXMD has outperformed RNAZ by 82.6 percentage points over the past year.
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About TherapeuticsMD
TXMD stock →TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
RNAZ vs TXMD FAQ
Which is bigger, TransCode Therapeutics or TherapeuticsMD?
TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $19.79M for TherapeuticsMD (TXMD).
Which stock has performed better over the past year, RNAZ or TXMD?
TXMD returned -3.93% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are TransCode Therapeutics and TherapeuticsMD in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.